← Eichor
Study identifier: NCT06208371 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM

Condition: Colorectal Neoplasms Malignant  ·  Sponsor: Sun Yat-sen University

PhasePhase 3
Planned participants117
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to investigate the effectiveness of localized interventions in improving the 5-year survival rate for colorectal cancer patients with ≥10 liver metastases. We aim to answer the following question: Can localized interventions, including surgery and/or ablation and/or stereotactic body radiotherapy (SBRT), enhance the 5-year survival rate compared to palliative chemotherapy alone in patients with ≥10 colorectal liver metastases (CRLM)? Participants in this study, who have achieved disease control through chemotherapy, will undergo either localized interventions (surgery and/or ablation and/or SBRT) or receive palliative chemotherapy alone. Researchers will compare the survival outcomes between these groups to determine the potential benefits of localized interventions for patients with ≥10 CRLM.

This description comes directly from the study's public registry record.

Talk to the study team

Yuhong Li, PhD  ·  87342487  ·  liyh@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-sen Cancer CenterGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06208371